Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1649132 | 0.90 | GPR119 (0.64) | GPR119CHEK2PDE4DPDE4APDE4B | |
| Hydrochloric Acid SCHEMBL14632585 | 0.88 | GPR119 (0.63) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL5530954 | 0.88 | CHEK2 (0.67) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL240683 | 0.87 | GPR119 (0.61) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL74203 | 0.86 | GPR119 (0.67) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL12533230 | 0.86 | GPR119 (0.67) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL264162 | 0.86 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL2735422 | 0.86 | GPR119 (0.67) | GPR119CHEK2ALDH1A1HRH3USP30 | |
| SCHEMBL1375476 | 0.86 | GPR119 (0.60) | GPR119CHEK2PDE4DPDE4APDE4B | |
| SCHEMBL7334976 | 0.86 | GPR119 (0.60) | GPR119CHEK2PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-06-25 | — | — | US | disclosed |
| CN-112469719-B | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-3797107-B1 | HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2022-08-10 | — | — | EP | disclosed |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2021-07-08 | — | — | US | disclosed |
| EP-3797107-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2021-03-31 | — | — | EP | disclosed |
| CN-112469719-A | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9951048-B1 | Isoquinolin-3-yl carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9487526-B2 | Quinoxaline derivatives as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2882722-B1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | TAKEDA PHARMACEUTICAL (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
| EP-2882722-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | Envoy Therapeutics Inc. (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014028479-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| EP-2069312-B1 | PYRIDIZINONE DERIVATIVES | CEPHALON INC (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2010048149-A2 | HETEROCYCLIC MODULATORS OF GPR119 FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-7297694-B2 | Pyridylfurans and pyrroles as Raf kinase inhibitors | SMITHKLINE BEECHUM P.L.C. (GB) | 2007-11-20 | — | — | US | disclosed |
| US-20040254186-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232469-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR119 25/4885CHEK2 2491/4885PDE4D 588/4885 |
| US-12018023-B2 | Heterocondensed pyridones compounds and their use as IDH inhibitors | IDH1, IDH2, IDH3A | GPR119 1812/4885CHEK2 379/4885PDE4D 3396/4885 |
| US-20180093970-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | GPR119 2568/4885CHEK2 2424/4885PDE4D 2668/4885 |
| US-20210206759-A1 | HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS | IDH1, IDH2, IDH3A | GPR119 1812/4885CHEK2 379/4885PDE4D 3396/4885 |
| US-20170035775-A1 | QUINOXALINE DERIVATIVES AS GPR6 MODULATORS | GPR6, GRM6, GPR65 | GPR119 25/4885CHEK2 2491/4885PDE4D 588/4885 |
| US-20180155323-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | GPR119 2568/4885CHEK2 2424/4885PDE4D 2668/4885 |
| US-20170313682-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | GPR119 2568/4885CHEK2 2424/4885PDE4D 2668/4885 |
| US-20040254186-A1 | Pyridylfurans and pyrroles as raf kinase inhibitors | BRAF, ARAF, RAF1 | GPR119 2931/4885CHEK2 376/4885PDE4D 1123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.